New Addition To NOXXON Pharma AG Supervisory Board Brings Significant U.S. Public Market Expertise

Berlin, Germany and Boston, USA - 10 December 2014 - NOXXON Pharma has appointed Don deBethizy to the Company's Supervisory Board.

In his last position as President and Chief Executive Officer of Santaris Pharma A/S, deBethizy initiated and managed the successful acquisition of the company by Roche. Previously, he was Executive Chairman of Danish bio-venture firm, Contera Pharma and oversaw its sale to Korean Bukwang Pharmaceutical. From 1997 to 2012, Dr. deBethizy was co-founder and CEO of Targacept, Inc. (NASDAQ:TRGT). He is currently on the Board of Directors of Newron Pharmaceuticals (SIX: NWRN).

Don deBethizy holds a BS degree in Biology from the University of Maryland and received a Ph.D. in Toxicology from Utah State University. He will join the current Supervisory Board of NOXXON which consists of seven industry and investor representatives.

"It is my pleasure to welcome Don to the team, as he is a highly qualified, experienced pharmaceutical company executive with significant experience of drug and technology development," said Iain Buchanan, CEO of NOXXON Pharma. "His past experience with Santaris' locked nucleic acid (LNA) platform and Targacept's NNR Therapeutics are particularly relevant, and will be increasingly useful to NOXXON as we will continue to further progress and develop our pipeline." "NOXXON has very promising compounds in development based on its unique Spielgelmer® platform, and the company is at an exciting inflection point," said Dr. deBethizy. "I look forward to contributing to Board discussions and helping the management with company strategy and product development."

- ENDS -

Notes for Editors:

About NOXXON Pharma

NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical-stage Spiegelmer® therapeutics:

• Lexaptepid pegol (NOX-H94), an anti-hepcidin Spiegelmer®, has completed a Phase IIa pilot study in cancer patients with anemia and is now being studied in EPO-hyporesponsive dialysis patients. Hepcidin is the key regulator of iron metabolism and responsible for the iron restriction leading to anemia of chronic disease.

• Olaptesed pegol (NOX-A12), an anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer®, has completed Phase IIa studies in two hematological cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). Studies for treatment of glioblastoma have also been designed and olaptesed pegol has received Orphan Drug Designation from the FDA and EMA for this indication. CXCL12 is a chemokine known to be involved in tumor invasion, metastasis and resistance to therapy.

• Emapticap pegol (NOX-E36), an anti-CCL2/MCP-1 (C-C chemokine ligand 2 / Monocyte Chemoattractant Protein-1) Spiegelmer®, has completed a Phase IIa proof-of-concept study in patients with type 2 diabetes with albuminuria and a Phase IIb study is in the planning stages. CCL2 is a pro-inflammatory chemokine involved in the recruitment of immune cells to inflamed tissues.

The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, and approximately 55 employees.

For more information, please visit: www.noxxon.com

Issued for and on behalf of NOXXON Pharma by Instinctif Partners.

For more information please contact:

NOXXON Pharma AG
Emmanuelle Delabre
T: +49-30-726247-0
[email protected]

Media Enquiries – Instinctif Partners:
Robert Mayer / Andreas Zunhammer
T: +49-89-30905189-13 / -11
[email protected]

Suggested Articles

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets. 

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.